CytRx Corporation (CYTR) Announces the Presentation of Favorable Results From Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at American Society of Clinical Oncology Conference
6/3/2013 7:21:40 AM
More...
|
CytRx Corporation (CYTR) Announces Initial Results From Pharmacokinetics Clinical Trial With Aldoxorubicin in Solid Tumors
5/21/2013 9:56:50 AM
More...
|
CytRx Corporation (CYTR) Issues Letter to Stockholders Providing Business Update
5/20/2013 10:25:35 AM
More...
|
CytRx Corporation (CYTR) Reports 2013 First Quarter Financial Results
5/9/2013 7:54:15 AM
More...
|
CytRx Corporation (CYTR) Ditches Lung Cancer Drug After Phase 2 Trial Failure
5/8/2013 10:48:49 AM
More...
|
CytRx Corporation (CYTR) Receives Recommendation From Data Safety Monitoring Committee to Complete International Phase 2b Trial With Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
5/6/2013 10:08:12 AM
More...
|
CytRx Corporation (CYTR) Reports 2012 Financial Results
3/11/2013 6:43:28 AM
More...
|
CytRx Corporation (CYTR) to Present at the Cowen and Company 33rd Annual Health Care Conference
3/1/2013 7:15:24 AM
More...
|
CytRx Corporation (CYTR) Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial With Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer
2/28/2013 9:48:11 AM
More...
|
CytRx Corporation (CYTR) to Present at the 2013 Leerink Swann and Company Global Healthcare Conference
2/6/2013 6:55:25 AM
More...
|
|